Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Califf

Showing results (481-490 of 567) with videos related to

Pageof 57
Sort By:
Clinical Chemistry|March 25, 1998
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa InvestigatorsR H Christenson, S H Duh, L K Newby, et al.
JAMA|March 13, 1996
Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigatorsW D Weaver, H D White, R G Wilcox, et al.
The American Journal of Cardiology|March 1, 1997
Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon PumpJ D Talley, E M Ohman, D B Mark, et al.
Journal of the American College of Cardiology|January 15, 2000
Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarctionD Hasdai, R M Califf, T D Thompson, et al.
Journal of the American College of Cardiology|September 19, 1998
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary ArteriesM Pfisterer, J L Cox, C B Granger, et al.
JAMA|August 13, 1997
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic ComplicationE J Topol, J J Ferguson, H F Weisman, et al.
Circulation|March 14, 1998
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-IK W Mahaffey, C B Granger, M A Sloan, et al.
Circulation|November 14, 1997
Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplastyG W Barsness, E D Peterson, E M Ohman, et al.
American Heart Journal|September 1, 1999
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary ArteriesK W Mahaffey, C B Granger, M A Sloan, et al.
European Heart Journal|February 10, 2000
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUITK M Akkerhuis, J W Deckers, E Boersma, et al.
Pageof 57

Showing results (481-490 of 567) with videos related to

Sort By:
Pageof 57
Clinical Chemistry|March 25, 1998
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa InvestigatorsR H Christenson, S H Duh, L K Newby, et al.
JAMA|March 13, 1996
Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigatorsW D Weaver, H D White, R G Wilcox, et al.
The American Journal of Cardiology|March 1, 1997
Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon PumpJ D Talley, E M Ohman, D B Mark, et al.
Journal of the American College of Cardiology|January 15, 2000
Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarctionD Hasdai, R M Califf, T D Thompson, et al.
Journal of the American College of Cardiology|September 19, 1998
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary ArteriesM Pfisterer, J L Cox, C B Granger, et al.
JAMA|August 13, 1997
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic ComplicationE J Topol, J J Ferguson, H F Weisman, et al.
Circulation|March 14, 1998
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-IK W Mahaffey, C B Granger, M A Sloan, et al.
Circulation|November 14, 1997
Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplastyG W Barsness, E D Peterson, E M Ohman, et al.
American Heart Journal|September 1, 1999
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary ArteriesK W Mahaffey, C B Granger, M A Sloan, et al.
European Heart Journal|February 10, 2000
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUITK M Akkerhuis, J W Deckers, E Boersma, et al.
Pageof 57